Drug
Naxitamab
Naxitamab: highest development phase Phase 2, developed by Y-mAbs Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Naxitamab NCT07537400 | Phase 2 | High-Risk Neuroblastoma |
| Naxitamab NCT04909515 | Phase 2 | Neuroblastoma |
| Naxitamab NCT05489887 | Phase 2 | Neuroblastoma |
| Naxitamab NCT07027748 | Phase 1 | Neuroblastoma |
Latest
No recent events.
Follow Naxitamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.